Martin & Co. Inc. TN Sells 10,302 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Martin & Co. Inc. TN decreased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,743 shares of the company's stock after selling 10,302 shares during the quarter. Martin & Co. Inc. TN owned approximately 0.20% of Omnicell worth $4,173,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Principal Financial Group Inc. grew its position in Omnicell by 4.0% in the 4th quarter. Principal Financial Group Inc. now owns 238,356 shares of the company's stock worth $10,612,000 after purchasing an additional 9,267 shares during the last quarter. New York State Teachers Retirement System grew its position in Omnicell by 2.4% in the 4th quarter. New York State Teachers Retirement System now owns 61,974 shares of the company's stock worth $2,759,000 after purchasing an additional 1,432 shares during the last quarter. Vontobel Holding Ltd. bought a new position in Omnicell in the 4th quarter worth about $297,000. Van ECK Associates Corp grew its position in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the last quarter. Finally, Shaker Investments LLC OH bought a new position in Omnicell in the 4th quarter worth about $550,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares of the company's stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.64% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on OMCL shares. Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Barclays upped their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, Benchmark reiterated a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $52.33.

Omnicell Stock Performance

NASDAQ:OMCL traded down $0.47 during midday trading on Thursday, reaching $39.65. The stock had a trading volume of 343,829 shares, compared to its average volume of 405,313. The firm's fifty day simple moving average is $43.21 and its 200-day simple moving average is $43.87. The stock has a market capitalization of $1.84 billion, a P/E ratio of 146.86, a PEG ratio of 7.59 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.